Accuracy of 68Ga-Pentixafor PET/CT for Subtypting Diagnosis in Patients With Primary Aldosteronism Concurrent With Autonomous Cortisol Secretion
NCT06635993 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 97
Last updated 2024-10-10
Summary
To evaluate the accuracy of 68Ga-Pentixafor PET-CT in the classification diagnosis of primary aldosteronism concurrent with autonomous cortisol secretion patient, using AVS and/or postoperative remission as the reference standard for classification diagnosis.
Conditions
- Primary Aldosteronism Concurrent With Autonomous Cortisol Secretion
Interventions
- DIAGNOSTIC_TEST
-
68Ga-Pentixafor PET/CT
The patients had a normal diet with no special preparation before 68Ga-Pentixafor PET/CT imaging. The dosage of intravenously injected 68Ga-Pentixafor was calculated based on the patient\'s weight (1.85 MBq \[0.05mCi\]/kg). Local PET/CT scanning of the upper abdomen was performed on a hybrid PET/CT scanner at 10 minutes after the injection of the intravenous tracer, respectively.
Sponsors & Collaborators
-
The First Affiliated Hospital of Zhengzhou University
collaborator OTHER -
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
collaborator OTHER -
The Third Xiangya Hospital of Central South University
collaborator OTHER -
The Affiliated Hospital Of Southwest Medical University
collaborator OTHER -
Qifu Li
lead OTHER
Principal Investigators
-
Qi fu Li, PhD · the Chongqing Primary Aldosteronism Study (CONPASS) Group
Eligibility
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2024-08-12
- Primary Completion
- 2026-08-12
- Completion
- 2027-08-12
Countries
- China
Study Locations
More Related Trials
-
[18F]AlF-NOTA-pentixather PET/CT in Patients With Suspected Primary Hyperaldosteronism
NCT05815069 ·Status: UNKNOWN ·Phase: NA
-
Non Invasive Imaging Methods for Detecting PA:a Clinical PET Study of 18F-Pentixather
NCT06581744 ·Status: RECRUITING ·Phase: NA
-
Application of Al18F-NOTA-Pentixafor PET/CT for Primary Aldosteronism
NCT06773663 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Somatostatin Receptor PET/CT in SSTR-Related Disease Patients
NCT06690957 ·Status: RECRUITING
-
Impact of [11C]-Methionine PET/MRI in the Detection of Pituitary Adenomas Secreting ACTH and Causing Cushing's Disease
NCT03346954 ·Status: COMPLETED ·Phase: NA
-
68Ga-Pentikra PET/CT Imaging Study in Healthy Subjects
NCT06856109 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
68Ga-DOTA-TOC PET/CT in Imaging Participants With Neuroendocrine Tumors
NCT03001349 ·Status: TERMINATED ·Phase: EARLY_PHASE1
-
Evaluation of [68Ga]Ga-PentixaFor PET Imaging for the Identification of Unilateral Adrenal Secretion of ALdosterON in Patients With Primary Aldosteronism
NCT06478875 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Use of [18F]FET PET-MRI to Improve Detection of Pituitary Adenomas in Cushing's Disease
NCT07108244 ·Status: ENROLLING_BY_INVITATION ·Phase: NA
-
Detection of Functioning Pituitary Microadenoma: PET/MRI Versus PET/CT
NCT03404414 ·Status: UNKNOWN ·Phase: PHASE1
-
68Ga-NOTA-exendin-4 PET/CT for the Localization of Insulinoma and Diagnosis of Nesidioblastosis
NCT02560376 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
Enhancing SUV Accuracy of PET/MR for Clinical Trial Qualification
NCT03603925 ·Status: COMPLETED
-
Defining Response Criteria for PET Scans for People With Neuroendocrine Tumors
NCT06448208 ·Status: ACTIVE_NOT_RECRUITING
-
SSTR PET/CT for Preoperative N Stage Evaluation in GEP-NETs
NCT06344832 ·Status: NOT_YET_RECRUITING
-
Use of 68Ga-dotatate PET Scan in Neuroendocrine Carcinoma of the GI Tract
NCT04069299 ·Status: COMPLETED
-
Pre-surgical Detection of Clear Cell Renal Cell Carcinoma (ccRCC) Using Radiolabeled G250-Antibody
NCT00606632 ·Status: COMPLETED ·Phase: PHASE3
-
Study to Measure the Safety of 68Ga-DOTA-TATE PET/CT in the Diagnosis of Tumors Expressing Somatostatin Receptors
NCT02810600 ·Status: COMPLETED
-
68Ga-HA-DOTATATE PET/CT in Adults With Neuroendocrine Tumors
NCT05673031 ·Status: RECRUITING
-
Dual-Tracer Theranostic PET
NCT05680675 ·Status: COMPLETED ·Phase: NA
-
68Ga-PSMA PET/CT for Ra223 Assessment
NCT04951817 ·Status: RECRUITING ·Phase: NA
-
Al18F-NOTA-LM3 PET/CT in Patients With Pheochromocytoma and Paraganglioma
NCT07288931 ·Status: RECRUITING ·Phase: NA
-
Dopamine D2 Receptors(D2R) Imaging in Nonfunctioning Pituitary Adenoma(NFPA)
NCT03714763 ·Status: UNKNOWN ·Phase: NA
-
PET/CT Imaging Study With Simultaneous Dual-nuclide Imaging Technique
NCT06914427 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
A Study Evaluating the Value of 68Ga-NOTA-RCCB6 PET Imaging for Targeting CD70 in the Clinical Staging, Therapeutic Evaluation, and Restaging of Renal Cell Carcinoma, and Comparing It with 68Ga-PSMA PET/CT Imaging
NCT06769893 ·Status: RECRUITING ·Phase: NA
-
Safety of 68Ga-DOTA-tyr3-Octreotide PET in Diagnosis of Solid Tumors
NCT01619865 ·Status: COMPLETED ·Phase: PHASE1/PHASE2